DISPERSE2-TIMI 33

DISPERSE2-TIMI 33 evaluated the safety, tolerability, and efficacy of AZD6140, an oral reversible ADP receptor antagonist, compared with clopidogrel in patients with non-ST segment elevation acute coronary syndrome.

DOWNLOAD SLIDE SET (PDF)

Key Study Publications

Cannon, C. P., Husted, S., Harrington, R. A., Scirica, B. M., Emanuelsson, H., Peters, G., Storey, R. F. Safety, tolerability, and initial efficacy of AZD6140, the first reversible oral adenosine diphosphate receptor antagonist, compared with clopidogrel, in patients with non-ST-segment elevation acute coronary syndrome: primary results of the DISPERSE-2 trial J Am Coll Cardiol. 2007;50(19):1844-51. Abstract